公开(公告)号：US20230338449A1

公开(公告)日：2023-10-26

申请号：US18214183

申请日：2023-06-26

Applicant: Housey Pharmaceutical Research Laboratories, L.L.C.

Inventor： Gerard M. Housey ,  Monica Elizabeth Balash

IPC: A61K36/28 ,  A61K31/40 ,  A61K38/28 ,  A61K45/06 ,  G01N33/50 ,  A61K38/26 ,  A61K31/155 ,  A61K31/4985

CPC classification number: A61K36/28 ,  A61K31/40 ,  A61K38/28 ,  A61K45/06 ,  G01N33/5008 ,  A61K38/26 ,  A61K31/155 ,  A61K31/4985 ,  G01N2333/4703 ,  A61K2300/00 ,  G01N2500/10

Abstract: This invention relates to plant extracts containing nutritionally beneficial or medicinally active compounds. Some of these extracts, or the purified compounds contained therein, may be used for the nutritional support, prevention, treatment, or possible cure of various metabolic and other diseases and disorders in human beings and animals, including type 1 and type 2 diabetes, by regulating insulin signaling. This regulatory effect may include modulations of the levels and/or activity of the Insulin Receptor (IR), the Insulin-like Growth Factor (IGF) Receptor, and/or the Insulin Receptor Substrate (IRS) proteins in cells and tissues in the body.

公开(公告)号：US20240293489A1

公开(公告)日：2024-09-05

申请号：US18664874

申请日：2024-05-15

Applicant: Housey Pharmaceutical Research Laboratories, L.L.C.

Inventor： Gerard M. Housey ,  Monica Elizabeth Balash

IPC: A61K36/28 ,  A61K31/155 ,  A61K31/40 ,  A61K31/4985 ,  A61K38/26 ,  A61K38/28 ,  A61K45/06 ,  G01N33/50

CPC classification number: A61K36/28 ,  A61K31/155 ,  A61K31/40 ,  A61K31/4985 ,  A61K38/26 ,  A61K38/28 ,  A61K45/06 ,  G01N33/5008 ,  A61K2300/00 ,  G01N2333/4703 ,  G01N2500/10

Abstract: This invention relates to plant extracts containing nutritionally beneficial or medicinally active compounds. Some of these extracts, or the purified compounds contained therein, may be used for the nutritional support, prevention, treatment, or possible curc of various metabolic and other diseases and disorders in human beings and animals, including type 1 and type 2 diabetes, by regulating insulin signaling. This regulatory effect may include modulations of the levels and/or activity of the Insulin Receptor (IR), the Insulin-like Growth Factor (IGF) Receptor, and/or the Insulin Receptor Substrate (IRS) proteins in cells and tissues in the body.

公开(公告)号：US20230248792A1

公开(公告)日：2023-08-10

申请号：US18116440

申请日：2023-03-02

Applicant: Housey Pharmaceutical Research Laboratories, L.L.C.

Inventor： Gerard M. Housey ,  Monica Elizabeth Balash

IPC: A61K36/282 ,  A23L33/00 ,  A61P3/10 ,  A61K9/00 ,  A61K33/26 ,  A61K33/30 ,  A61K33/32 ,  A61K33/34 ,  A61K36/287

CPC classification number: A61K36/282 ,  A23L33/30 ,  A61K9/0053 ,  A61K33/26 ,  A61K33/30 ,  A61K33/32 ,  A61K33/34 ,  A61K36/287 ,  A61P3/10

Abstract: This invention relates to plant extracts containing nutritionally beneficial or medicinally active compounds. Some of these extracts, or the purified compounds contained therein, may be used for the nutritional support, prevention, treatment, or possible cure of various metabolic and other diseases and disorders in human beings and animals, including type 1 and type 2 diabetes, by regulating insulin signaling. This regulatory effect may include modulations of the levels and/or activity of the Insulin Receptor (IR), the Insulin-like Growth Factor (IGF) Receptor, and/or the Insulin Receptor Substrate (IRS) proteins in cells and tissues in the body.

公开(公告)号：US11633446B2

公开(公告)日：2023-04-25

申请号：US16612545

申请日：2018-05-11

Applicant: Housey Pharmaceutical Research Laboratories, L.L.C.

Inventor： Gerard M. Housey ,  Monica Elizabeth Balash

IPC: A61K36/282 ,  A23L33/00 ,  A61P3/10 ,  A61K9/00 ,  A61K33/26 ,  A61K33/30 ,  A61K33/32 ,  A61K33/34 ,  A61K36/287

Abstract: This invention relates to plant extracts containing nutritionally beneficial or medicinally active compounds. Some of these extracts, or the purified compounds contained therein, may be used for the nutritional support, prevention, treatment, or possible cure of various metabolic and other diseases and disorders in human beings and animals, including type 1 and type 2 diabetes, by regulating insulin signaling. This regulatory effect may include modulations of the levels and/or activity of the Insulin Receptor (IR), the Insulin-like Growth Factor (IGF) Receptor, and/or the Insulin Receptor Substrate (IRS) proteins in cells and tissues in the body.